Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11,117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Response to anti-IL17 therapy in inflammatory disease is not strongly impacted by genetic background.
Zhang C, Shestopaloff K, Hollis B, Kwok CH, Hon C, Hartmann N, Tian C, Wozniak M, Santos L, West D, Gardiner S, Mallon AM, Readie A, Martin R, Nichols T, Beste MT, Zierer J, Ferrero E, Vandemeulebroecke M, Jostins-Dean L. Zhang C, et al. Among authors: martin r. Am J Hum Genet. 2023 Oct 5;110(10):1817-1824. doi: 10.1016/j.ajhg.2023.08.010. Epub 2023 Sep 1. Am J Hum Genet. 2023. PMID: 37659414 Free PMC article.
Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.
Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, Readie A, Martin R, Mpofu S, Richards HB; MEASURE 1 study group. Braun J, et al. Among authors: martin r. Ann Rheum Dis. 2017 Jun;76(6):1070-1077. doi: 10.1136/annrheumdis-2016-209730. Epub 2016 Dec 13. Ann Rheum Dis. 2017. PMID: 27965257 Free article. Clinical Trial.
Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.
Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Martin R, Readie A, Richards HB, Porter B; Measure 2 Study Group. Marzo-Ortega H, et al. Among authors: martin r. Arthritis Care Res (Hoboken). 2017 Jul;69(7):1020-1029. doi: 10.1002/acr.23233. Epub 2017 Jun 7. Arthritis Care Res (Hoboken). 2017. PMID: 28235249 Free PMC article. Clinical Trial.
Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison.
Braun J, Haibel H, de Hooge M, Landewé R, Rudwaleit M, Fox T, Readie A, Richards HB, Porter B, Martin R, Poddubnyy D, Sieper J, van der Heijde D. Braun J, et al. Among authors: martin r. Arthritis Res Ther. 2019 Jun 7;21(1):142. doi: 10.1186/s13075-019-1911-1. Arthritis Res Ther. 2019. PMID: 31174584 Free PMC article. Clinical Trial.
Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS).
Baraliakos X, Østergaard M, Gensler LS, Poddubnyy D, Lee EY, Kiltz U, Martin R, Sawata H, Readie A, Porter B; SURPASS Study Group. Baraliakos X, et al. Among authors: martin r. Clin Drug Investig. 2020 Mar;40(3):269-278. doi: 10.1007/s40261-020-00886-7. Clin Drug Investig. 2020. PMID: 31983056
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, Paul C, Giamarellos Bourboulis EJ, Villani AP, Schwinn A, Ruëff F, Pillay Ramaya L, Reich A, Lobo I, Sinclair R, Passeron T, Martorell A, Mendes-Bastos P, Kokolakis G, Becherel PA, Wozniak MB, Martinez AL, Wei X, Uhlmann L, Passera A, Keefe D, Martin R, Field C, Chen L, Vandemeulebroecke M, Ravichandran S, Muscianisi E. Kimball AB, et al. Among authors: martin r. Lancet. 2023 Mar 4;401(10378):747-761. doi: 10.1016/S0140-6736(23)00022-3. Epub 2023 Feb 3. Lancet. 2023. PMID: 36746171 Clinical Trial.
Assessing the validity and clinical meaningfulness of skin pain response (NRS30) assessed using numerical rating scale in hidradenitis suppurativa: Results from the SUNSHINE and SUNRISE trials.
Wei X, Passera A, Muscianisi E, Uhlmann L, Chen L, Moreno SG, Martin R, Vandemeulebroecke M, Keefe D, Ravichandran S, Wozniak MB. Wei X, et al. Among authors: martin r. J Am Acad Dermatol. 2023 Dec;89(6):1285-1287. doi: 10.1016/j.jaad.2023.07.1035. Epub 2023 Aug 12. J Am Acad Dermatol. 2023. PMID: 37579844 Free article. No abstract available.
A framework for longitudinal latent factor modelling of treatment response in clinical trials with applications to Psoriatic Arthritis and Rheumatoid Arthritis.
Falck F, Zhu X, Ghalebikesabi S, Kormaksson M, Vandemeulebroecke M, Zhang C, Martin R, Gardiner S, Kwok CH, West DM, Santos L, Tian C, Pang Y, Readie A, Ligozio G, Gandhi KK, Nichols TE, Mallon AM, Kelly L, Ohlssen D, Nicholson G. Falck F, et al. Among authors: martin r. J Biomed Inform. 2024 Apr 18;154:104641. doi: 10.1016/j.jbi.2024.104641. Online ahead of print. J Biomed Inform. 2024. PMID: 38642627 Free article.
11,117 results
You have reached the last available page of results. Please see the User Guide for more information.